Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML-long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)†.

A Thiel, J Schetelig, W Pönisch, Kerstin Schäfer-Eckart (Co-author), W Aulitzky, N Peter, A Schulze, G Maschmeyer, S Neugebauer, R Herbst, A Hänel, A Morgner, F Kroschinsky, M Bornhäuser, T Lange, Martin Wilhelm (Co-author), D Niederwieser, G Ehninger, F Fiedler, M Hänel

Research output: Contribution to journalOriginal Article (Journal)peer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)143-140
JournalANNALS OF ONCOLOGY
Volume26
Issue number7
DOIs
Publication statusPublished - 2015

Keywords

  • ACUTE MYELOID-LEUKEMIA
  • HIGH-DOSE CYTARABINE
  • G-CSF
  • FLUDARABINE
  • TRIAL
  • CHEMOTHERAPY

Cite this